| The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling RJ Shaw, JG Paez, M Curto, A Yaktine, WM Pruitt, I Saotome, JP O'Bryan, ... Developmental cell 1 (1), 63-72, 2001 | 413 | 2001 |
| A diacylglycerol-protein kinase C-RasGRP1 pathway directs Ras activation upon antigen receptor stimulation of T cells JP Roose, M Mollenauer, VA Gupta, J Stone, A Weiss Molecular and cellular biology 25 (11), 4426-4441, 2005 | 301 | 2005 |
| Cell of origin and genetic alterations in the pathogenesis of multiple myeloma BG Barwick, VA Gupta, PM Vertino, LH Boise Frontiers in immunology 10, 1121, 2019 | 230 | 2019 |
| Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma NS Joseph, JL Kaufman, MV Dhodapkar, CC Hofmeister, DK Almaula, ... Journal of Clinical Oncology 38 (17), 1928-1937, 2020 | 228 | 2020 |
| Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone TM Schmidt, BG Barwick, N Joseph, LT Heffner, CC Hofmeister, L Bernal, ... Blood Cancer Journal 9 (12), 94, 2019 | 176 | 2019 |
| Daratumumab in multiple myeloma AK Nooka, JL Kaufman, CC Hofmeister, NS Joseph, TL Heffner, VA Gupta, ... Cancer 125 (14), 2364-2382, 2019 | 156 | 2019 |
| Multiple myeloma immunoglobulin lambda translocations portend poor prognosis BG Barwick, P Neri, NJ Bahlis, AK Nooka, MV Dhodapkar, DL Jaye, ... Nature communications 10 (1), 1911, 2019 | 153 | 2019 |
| Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax SM Matulis, VA Gupta, AK Nooka, HV Hollen, JL Kaufman, S Lonial, ... Leukemia 30 (5), 1086-1093, 2016 | 140 | 2016 |
| Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma VA Gupta, SM Matulis, JE Conage-Pough, AK Nooka, JL Kaufman, ... Blood, The Journal of the American Society of Hematology 129 (14), 1969-1979, 2017 | 116 | 2017 |
| PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity CR Funk, S Wang, KZ Chen, A Waller, A Sharma, CL Edgar, VA Gupta, ... Blood, The Journal of the American Society of Hematology 139 (4), 523-537, 2022 | 102 | 2022 |
| Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory … AK Nooka, NS Joseph, JL Kaufman, LT Heffner, VA Gupta, C Gleason, ... Cancer 125 (17), 2991-3000, 2019 | 93 | 2019 |
| Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma R Bajpai, A Sharma, A Achreja, CL Edgar, C Wei, AA Siddiqa, VA Gupta, ... Nature communications 11 (1), 1228, 2020 | 86 | 2020 |
| The juxtamembrane wedge negatively regulates CD45 function in B cells ML Hermiston, AL Tan, VA Gupta, R Majeti, A Weiss Immunity 23 (6), 635-647, 2005 | 76 | 2005 |
| Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression VA Gupta, BG Barwick, SM Matulis, R Shirasaki, DL Jaye, JJ Keats, ... Blood, The Journal of the American Society of Hematology 137 (26), 3604-3615, 2021 | 64 | 2021 |
| Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents R Mina, NS Joseph, JL Kaufman, VA Gupta, LT Heffner, CC Hofmeister, ... Cancer 125 (3), 416-423, 2019 | 53 | 2019 |
| Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma SM Matulis, VA Gupta, P Neri, NJ Bahlis, P Maciag, JD Leverson, ... Leukemia 33 (5), 1291-1296, 2019 | 45 | 2019 |
| Aberrant extrafollicular B cells, immune dysfunction, myeloid inflammation, and MyD88-mutant progenitors precede Waldenstrom macroglobulinemia A Kaushal, AK Nooka, AR Carr, KE Pendleton, BG Barwick, J Manalo, ... Blood cancer discovery 2 (6), 600-615, 2021 | 28 | 2021 |
| Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma KG Ponder, SM Matulis, S Hitosugi, VA Gupta, C Sharp, F Burrows, ... Cancer Biology & Therapy 17 (7), 769-777, 2016 | 27 | 2016 |
| Chromatin accessibility identifies regulatory elements predictive of gene expression and disease outcome in multiple myeloma BG Barwick, VA Gupta, SM Matulis, JC Patton, DR Powell, Y Gu, DL Jaye, ... Clinical Cancer Research 27 (11), 3178-3189, 2021 | 18 | 2021 |
| BCL2 family inhibitors in the biology and treatment of multiple myeloma VA Gupta, J Ackley, JL Kaufman, LH Boise Blood and Lymphatic Cancer: Targets and Therapy, 11-24, 2021 | 18 | 2021 |
